Loading…
Matinas Biopharma Holdings is projected to rise to $1.24 by 2027, a +64% move from its current price of $0.755. MTNB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.7151 | $0.7548 | $0.7968 | -0.02% |
| Jul 13 | $0.6991 | $0.7547 | $0.8146 | -0.04% |
| Jul 14 | $0.6871 | $0.7545 | $0.8286 | -0.07% |
| Jul 15 | $0.677 | $0.7543 | $0.8405 | -0.09% |
| Jul 16 | $0.6683 | $0.7542 | $0.8511 | -0.11% |
| Jul 17 | $0.6605 | $0.754 | $0.8608 | -0.13% |
| Jul 18 | $0.6534 | $0.7539 | $0.8698 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6534 | $0.7539 | $0.8698 | -0.15% |
| Week 2 | $0.6148 | $0.7527 | $0.9215 | -0.30% |
| Week 3 | $0.5866 | $0.7516 | $0.9629 | -0.45% |
| Week 4 | $0.5637 | $0.7504 | $0.999 | -0.61% |
| Week 5 | $0.5442 | $0.7493 | $1.03 | -0.76% |
| Week 6 | $0.527 | $0.7482 | $1.06 | -0.91% |
| Week 7 | $0.5116 | $0.747 | $1.09 | -1.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The LNC delivery platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Matinas Biopharma Holdings, MTNB, is a small-cap clinical-stage biopharmaceutical company focused on its lipid nanocrystal (LNC) platform for delivering biologically active therapies. The stock trades at $0.755 and has a market capitalization of $4.02M, with a market position ranked 5496. The current price and the long-range forecast imply a neutral near term with potential upside over the longer horizon.
A major floor 37.0% below — a decisive break under it would weaken the trend.
The nearest floor, 20.0% below — buyers have tended to step in here.
The nearest ceiling, 15.5% above — a clean break opens room to run.
A major ceiling 34.0% above — clearing it would confirm fresh momentum.
Key MTNB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MTNB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6494 | Buy | $0.6686 | Buy |
| MA 10 | $0.643 | Buy | $0.6572 | Buy |
| MA 20 | $0.668 | Buy | $0.6668 | Buy |
| MA 50 | $0.6825 | Buy | $0.669 | Buy |
| MA 100 | $0.6322 | Buy | $0.6886 | Buy |
| MA 200 | $0.8474 | Sell | $0.8693 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.02 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 111.54 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 16.15 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.36 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 78.61 | Sell |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 0.66 | Buy |
| ADX (14) | 17.50 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day range for MTNB runs from $0.5286 to $1.08. The RSI(14) is 60, with a 50-day moving average of $0.6825 and a 200-day moving average of $0.8474. Nearby technical support is at $0.604 and resistance at $0.872. The sentiment is BULLISH in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.49 | $0.755 | $1.11 | 0% | Neutral | |
| $0.8975 | $1.24 | $1.84 | +64% | Bullish | |
| $0.8636 | $1.27 | $2.01 | +68% | Bullish | |
| $0.7836 | $1.21 | $2.02 | +60% | Bullish | |
| $0.8883 | $1.44 | $2.49 | +90% | Bullish | |
| $0.7215 | $1.22 | $2.19 | +62% | Bullish | |
| $0.6913 | $1.22 | $2.26 | +61% | Bullish | |
| $0.9964 | $1.83 | $3.48 | +142% | Bullish | |
| $1.09 | $2.09 | $4.07 | +176% | Bullish | |
| $1.19 | $2.36 | $4.71 | +212% | Bullish | |
| $1.26 | $2.80 | $6.16 | +271% | Bullish | |
| $2.36 | $5.26 | $12.09 | +596% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.49 | $0.755 | $0.8667 | +0.00% |
| August 2026 | $0.56 | $0.6787 | $0.8567 | -10.11% |
| September 2026 | $0.6023 | $0.7402 | $0.9539 | +9.07% |
| October 2026 | $0.6216 | $0.7733 | $1.01 | +4.47% |
| November 2026 | $0.6051 | $0.7606 | $1.01 | -1.64% |
| December 2026 | $0.6477 | $0.8221 | $1.11 | +8.08% |
Click any year to see its month-by-month MTNB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MTNB is projected to trade between $0.49 and $1.11, averaging $0.755 — a potential gain of 0% from today's $0.755. Price action looks broadly range-bound.
Matinas Biopharma Holdings's 2027 outlook centres on $1.24, within a $0.8975 to $1.84 range. That is up +64% on the projected 2026 average. That marks a +64% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, MTNB could reach as high as $2.01, with a base case around $1.27 and support toward $0.8636 — roughly +68% from $0.755. Momentum favours further upside here.
Expect MTNB to range from $0.7836 to $2.02 through 2029. The $1.21 average target implies a +60% move from current prices. That is -4% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The MTNB price prediction for 2030 points to an average of $1.44 (low $0.8883, high $2.49) — a potential gain of +90% on today's $0.755. Momentum favours further upside here.
In 2031, MTNB is projected to trade between $0.7215 and $2.19, averaging $1.22 — a potential gain of +62% from today's $0.755. That is -15% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Matinas Biopharma Holdings's 2032 outlook centres on $1.22, within a $0.6913 to $2.26 range. That is 0% versus the projected 2031 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2033, MTNB could reach as high as $3.48, with a base case around $1.83 and support toward $0.9964 — roughly +142% from $0.755. Buyers look set to stay in control over this stretch.
Expect MTNB to range from $1.09 to $4.07 through 2034. The $2.09 average target implies a +176% move from current prices. That is up +14% on the projected 2033 average. Momentum favours further upside here.
The MTNB price prediction for 2035 points to an average of $2.36 (low $1.19, high $4.71) — a potential gain of +212% on today's $0.755. Buyers look set to stay in control over this stretch.
In 2040, MTNB is projected to trade between $1.26 and $6.16, averaging $2.80 — a potential gain of +271% from today's $0.755. That is up +19% on the projected 2035 average. Momentum favours further upside here.
Matinas Biopharma Holdings's 2050 outlook centres on $5.26, within a $2.36 to $12.09 range. That is up +87% on the projected 2040 average. That marks a +596% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MTNB today (≈ 1,324.503311 MTNB) could be worth
$6,960.83
+$5,960.83 (+596%) by 2050 · US Dollar
Based on the average projected MTNB price of $5.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MTNBwould be worth at today's price.
$1,000 invested in MTNB on Jul 10, 2025 (≈ 970.873813 MTNB) would be worth
$733.01
-$266.99 (-26.7%) today · 0.73× · US Dollar
Based on a MTNB entry price of $1.03 vs. today's $0.755.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.634 | $1,190.85 | +19.1% |
| 1 month ago | $0.795 | $949.69 | -5.0% |
| 3 months ago | $0.5 | $1,510 | +51.0% |
| 6 months ago | $0.65 | $1,161.54 | +16.2% |
| 1 year ago | $1.03 | $733.01 | -26.7% |
| All time (5.0y) ago | $38.9 | $19.41 | -98.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MTNB forecast.
Our base-case forecast reaches $1.50 around 2033.
Implied market cap at $1.50: $9.61M
Forecasts show a path of gradual to strong upside over the coming years. For 2026 the avg price is $0.755 with a neutral sentiment, while 2027–2029 show bullish momentum with avg prices of $1.24, $1.27 and $1.21 respectively and ROIs of 63.9%, 67.6% and 60.2%. The outlook strengthens into 2030 with an avg of $1.44 and a 90.3% ROI, then continues higher to 2040 with an avg of $2.80 and a 271.5% ROI, and to 2050 with an avg of $5.26 and a 596.1% ROI.
These are projections and not guarantees, and they reflect rising expectations for growth alongside the company’s ongoing product development programs.
Tap a question to reveal the answer.
In 2030, the forecast shows an avg price of $1.44 with a min of $0.8883 and a max of $2.49; the ROI is 90.3% and sentiment is BULLISH.
The longer-term forecasts are BULLISH with growing avg prices and ROIs (e.g., 2027 avg $1.24 with 63.9% ROI, 2040 avg $2.80 with 271.5% ROI, 2050 avg $5.26 with 596.1% ROI). Near term 2026 is Neutral with avg $0.755 and ROI 0%.
The 2050 forecast shows a max of $12.09, with an avg of $5.26 and a ROI of 596.1%. Reaching $10 by 2050 is within the projected max, but these figures are not guarantees.
MTNB’s current price is $0.755 and its market cap is $4.02M.
For 2027 the forecasted avg price is $1.24 with a min of $0.8975 and a max of $1.84; the ROI is 63.9% and sentiment is BULLISH.
Matinas Biopharma Holdings Community Discussion
0Share your Matinas Biopharma Holdings price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.